Kanjinti Side Effects
Generic Name: trastuzumab
Medically reviewed by Drugs.com. Last updated on Sep 23, 2020.
Note: This document contains side effect information about trastuzumab. Some of the dosage forms listed on this page may not apply to the brand name Kanjinti.
For the Consumer
Applies to trastuzumab: intravenous powder for solution
Warning
Intravenous route (Powder for Solution)
Administration of trastuzumab products can result in subclinical and clinical cardiac failure, with the greatest risk and severity upon concurrent administration with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue trastuzumab-dkst in patients receiving adjuvant therapy and withhold trastuzumab-dkst for a clinically significant decrease in left ventricular function. Serious and fatal infusion reactions and pulmonary toxicity may occur during or within 24 hours after administration. Discontinue trastuzumab-dkst if signs of anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome are noted. Exposure during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.
Side effects requiring immediate medical attention
Along with its needed effects, trastuzumab (the active ingredient contained in Kanjinti) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking trastuzumab:
More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- chest pain
- chills
- cough
- cracked lips
- decreased frequency or amount of urine
- diarrhea
- difficult or labored breathing
- difficulty in swallowing
- dry mouth
- fever
- headache
- hoarseness
- increased blood pressure
- increased thirst
- irregular heartbeat
- loss of appetite
- lower back or side pain
- mood changes
- muscle aches, pain, or cramps
- nausea
- numbness or tingling in the hands, feet, or lips
- painful or difficult urination
- pale skin
- peeling of the skin
- pinpoint red spots on the skin
- seizures
- sore throat
- sores, ulcers, or white spots on the lips, tongue, or inside the mouth
- stuffy or runny nose
- swelling of the face, fingers, or lower legs
- swollen glands
- tightness in the chest
- troubled breathing
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual tiredness or weakness
- vomiting
- weight gain
Less common
- Bladder pain
- bloody nose
- blurred vision
- body aches or pain
- burning or stinging of the skin
- cloudy urine
- dilated neck veins
- dizziness
- ear congestion
- extreme tiredness or weakness
- fainting
- fast, irregular, pounding, or racing heartbeat or pulse
- frequent urge to urinate
- general feeling of discomfort or illness
- irregular breathing
- joint pain
- loss of voice
- nasal congestion
- nervousness
- pain or tenderness around the eyes and cheekbones
- painful cold sores or blisters on the lips, nose, eyes, or genitals
- pounding in the ears
- shivering
- sneezing
- sweating
- trouble sleeping
Rare
- Chest discomfort
- hives, itching, skin rash
- joint stiffness or swelling
- neck tenderness or swelling
- redness of the skin
- tightness in the chest
Side effects not requiring immediate medical attention
Some side effects of trastuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- difficulty in moving
- feeling of warmth
- muscle stiffness
- redness of the face, neck, arms and occasionally, upper chest
- sudden sweating
Less common
- Acne
- back pain
- belching
- bone pain
- constipation
- discoloration of the fingernails or toenails
- heartburn
- indigestion
- lack or loss of strength
- muscle spasm
- stomach upset or pain
- upper stomach pain
For Healthcare Professionals
Applies to trastuzumab: intravenous powder for injection
General
The most common adverse events were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, stomatitis, weight loss, thrombocytopenia, mucosal inflammation, nasopharyngitis, dysgeusia, and myalgia.[Ref]
Hematologic
Very common (10% or more): Neutropenia (78%), leukopenia (52%), anemia (36%), febrile neutropenia (23%), thrombocytopenia (16%)
Frequency not reported: Hypoprothrombinemia[Ref]
Cardiovascular
Very common (10% or more): LVEF decrease (44%), congestive heart failure (28%), cardiomyopathy (15%), peripheral edema (10%), tachycardia (10%)
Common (1% to 10%): Hypertension, hypotension, asymptomatic cardiac dysfunction, ejection fraction decreased, palpitation, cardiac arrhythmia, cardiac failure, heart beat irregular, cardiac flutter, lymphedema, hot flush, thrombotic adverse event, supraventricular tachyarrhythmia, vasodilation
Uncommon (0.1% to 1%): Ventricular dysfunction, pericardial effusion
Frequency not reported: Cardiogenic shock, pericarditis, bradycardia, gallop rhythm present, S3 gallop[Ref]
Hypersensitivity
Very common (10% or more): Infusion-related reactions (54%)
Common (1% to 10%): Hypersensitivity, allergic reaction
Frequency not reported: Anaphylactic reaction, anaphylactic shock[Ref]
Respiratory
Very common (10% or more): Cough (43%), dyspnea (42%), rhinitis (22%), Grade 2 to 5 pulmonary toxicity (14%), nasopharyngitis (13%), wheezing, epistaxis, rhinorrhea
Common (1% to 10%): Pharyngolaryngeal pain, sinusitis, epistaxis, upper respiratory infection, rhinitis, asthma, lung disorder, pleural effusion
Uncommon (0.1% to 1%): Pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitis
Frequency not reported: Pulmonary insufficiency, pulmonary fibrosis, respiratory distress, respiratory failure, lung infiltration, acute pulmonary edema, acute respiratory distress syndrome, bronchospasm, hypoxia, oxygen saturation decreased, laryngeal edema, pulmonary edema, orthopnea
Postmarketing reports: Bronchospasm, hypoxia, pleural effusions, non-cardiogenic pulmonary edema[Ref]
Immunologic
Very common (10% or more): Infection (47%), herpes simplex (38%), antibody to trastuzumab (the active ingredient contained in Kanjinti) (15%), flu syndrome (12%)
Common (1% to 10%): Neutropenic sepsis, postoperative wound infection, herpes zoster
Uncommon (0.1% to 1%): Sepsis[Ref]
Renal
Very common (10% or more): Renal impairment/failure (18%)
Common (1% to 10%): Grade 3 or 4 renal failure, renal disorder, hyperbilirubinemia
Frequency not reported: Glomerulonephritis membranous, glomerulonephropathy, renal failure
Postmarketing reports: Nephrotic syndrome with pathological evidence of glomerulopathy[Ref]
Gastrointestinal
Very common (10% or more): Nausea (76%), vomiting (53%), diarrhea (45%), abdominal pain (34%), stomatitis (24%), anorexia (14%)
Common (1% to 10%): Constipation, dyspepsia, dysphagia, lip swelling, pancreatitis, hemorrhoids, dry mouth[Ref]
Nervous system
Very common (10% or more): Headache (44%), asthenia (42%), fatigue (35%), insomnia (29%), dizziness (24%), paresthesia (23%), peripheral neuritis (23%), neuropathy (13%), dysgeusia (10%), dizziness (13%), tremor, hypoesthesia
Common (1% to 10%): Hypertonia, somnolence, ataxia
Rare (less than 0.1%): Paresis
Frequency not reported: Brain edema[Ref]
Dermatologic
Very common (10% or more): Rash (38%), nail changes (12%), acne (11%), rash/desquamation (11%), erythema, swelling face, palmar-plantar erythrodysesthesia syndrome, alopecia
Common (1% to 10%): Pruritus, dry skin, ecchymosis, hyperhidrosis, maculopapular rash, onychoclasis, dermatitis, contusion, skin infection, erysipelas, cellulitis
Uncommon (0.1% to 1%): Urticaria
Frequency not reported: Angioedema[Ref]
Musculoskeletal
Very common (10% or more): Arthralgia (37%), back pain (34%), bone pain (24%), muscle tightness, myalgia
Common (1% to 10%): Muscle spasm, neck pain, pain in extremity, arthritis[Ref]
Metabolic
Very common (10% or more): Anorexia (31%), hypokalemia (28%), weight loss (23%)
Frequency not reported: Hyperkalemia
Postmarketing reports: Volume overload[Ref]
Other
Very common (10% or more): Asthenia (62%), pain (61%), fever (56%), chills (41%), accidental injury (13%)
Common (1% to 10%): Malaise
Uncommon (0.1% to 1%): Deafness
Rare (less than 0.1%): Sudden death
Postmarketing reports: Oligohydramnios or oligohydramnios sequence (including pulmonary hypoplasia, skeletal abnormalities, and neonatal death)[Ref]
Hepatic
Common (1% to 10%): Hepatocellular injury, hepatitis, liver tenderness
Rare (less than 0.1%): Jaundice
Frequency not reported: Hepatic failure[Ref]
Ocular
Very common (10% or more): Conjunctivitis, lacrimation increased
Common (1% to 10%): Dry eye
Frequency not reported: Papilledema, retinal hemorrhage[Ref]
Genitourinary
Common (1% to 10%): Breast inflammation/mastitis, urinary tract infection, cystitis[Ref]
Psychiatric
Very common (10% or more): Depression (20%), insomnia (14%)
Common (1% to 10%): Anxiety, thinking abnormal
Uncommon (0.1% to 1%): Depression[Ref]
Endocrine
Uncommon (0.1% to 1%): Autoimmune thyroiditis[Ref]
Oncologic
Frequency not reported: Malignant neoplasm progression, neoplasm progression[Ref]
References
1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. "Product Information. Ogivri (trastuzumab)." Mylan GmbH, Morgantown, WV.
3. Cerner Multum, Inc. "Australian Product Information." O 0
4. "Product Information. Herceptin (trastuzumab)." Genentech, South San Francisco, CA.
Frequently asked questions
- How long can you stay on Herceptin and Perjeta?
- How many biosimilars have been approved in the United States?
- How long does Herceptin stay in your body?
- What is Herceptin? Is Herceptin a chemo drug? How does it work?
- Does Herceptin (trastuzumab) stop menstrual periods?
- How effective is Herceptin for Breast & Gastric Cancer?
- Do Herceptin (trastuzumab) injections hurt?
- How is Herceptin Injection and Herceptin Hylecta administered?
- What is the difference between Ogivri and Herceptin?
More about Kanjinti (trastuzumab)
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- FDA Approval History
Consumer resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.